ライブ

BioPharma DiveVerge, following trial failure, rebrands its AI drug discovery ambitions BioPharma DiveFDA delays decision on AstraZeneca breast cancer pill FierceBiotechKordata Dynamics launches with neural-focused AI clinical trial model Clinical OMICsDual CA19-9 Threshold Improves Risk Stratification in Pancreatic Cancer Clinical OMICsCD169-Positive Macrophages Attacking Melanoma Imaged in Living Tissue Clinical OMICsGuardant Nabs Key ACS Nod and Liquid Biopsy Approval Clinical OMICsAI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response BioPharma DiveCardio drugmaker Kardigan plans to go public BioPharma DiveKailera’s three-pronged obesity shot shows promise in early trial BioPharma DiveApogee eczema drugs gets Blackstone backing, heads to Phase 3 Endpoints NewsAstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave Endpoints NewsApogee secures Blackstone capital to move Dupixent rival into Phase 3

Clinical OMICs 2026年5月27日

AI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response

A new AI foundation model called MutationProjector converts tumor mutation profiles into biologically meaningful representations that predict therapy response,...

A new AI foundation model called MutationProjector converts tumor mutation profiles into biologically meaningful representations that predict therapy response, classify cancer subtypes, and uncover complex mutation patterns linked to immunotherapy resistance, potentially expanding the clinical utility of cancer genomic sequencing. The post AI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response appeared first on Inside Precision Medicine .